 |
|
Phenelzine vs Placebo in 50 Patients With Bulimia
B. Timothy Walsh, MD;
Madeline Gladis, MA;
Steven P. Roose, MD;
Jonathan W. Stewart, MD;
Fay Stetner, MS;
Alexander H. Glassman, MD
Arch Gen Psychiatry. 1988;45(5):471-475.
Abstract
• To examine the efficacy of the monoamine oxidase inhibitor phenelzine sulfate in the treatment of bulimia, a doubleblind, placebo-controlled trial was conducted. In 50 women who completed the trial, phenelzine was significantly superior to placebo in the reduction of binge frequency (64% vs 5%), in the fraction of patients who had ceased bingeing at the end of the trial (35% vs 4%), and in several measures of psychological state. The superiority of phenelzine over placebo was not confined to a depressed subgroup of patients. Although no patient experienced a hypertensive crisis during the study, other side effects of phenelzine were problematic and limit the usefulness of phenelzine in this population.
Author Affiliations
From The New York State Psychiatric Institute and the College of Physicians & Surgeons, Columbia University, New York.
Footnotes
Accepted for publication Nov 25, 1987.
Reprints not available.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Treatment of Bulimia Nervosa:: Psychological and Psychopharmacologic Considerations
Phillips et al.
Journal of Adolescent Research 2003;18:261-279.
ABSTRACT
A Placebo-Controlled Study of Fluoxetine in Continued Treatment of Bulimia Nervosa After Successful Acute Fluoxetine Treatment
Romano et al.
Am. J. Psychiatry 2002;159:96-102.
ABSTRACT
| FULL TEXT
Fluoxetine in the Treatment of Bulimia Nervosa: A Multicenter, Placebo-Controlled, Double-blind Trial
Fluoxetine Bulimia Nervosa Collaborative Study Gro
Arch Gen Psychiatry 1992;49:139-147.
ABSTRACT
A Comparison Study of Antidepressants and Structured Intensive Group Psychotherapy in the Treatment of Bulimia Nervosa
Mitchell et al.
Arch Gen Psychiatry 1990;47:149-157.
ABSTRACT
|
